Amy Sheng (left) is Head of the CRO Program at Sino Biological US Inc. (PA, USA), and has expertise in cell, molecular biology, immunology and biochemistry. In this interview, Amy discusses the ...
Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...
Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal antibodies are derived from hybridoma technology, the recombinant antibodies are ...
The past decade has seen a dramatic acceleration in DNA sequencing capability, together with significant advances in genome editing tools such as CRISPR. However, DNA synthesis technologies have been ...
In September 1970, Janet Mertz joined the biochemistry department at Stanford University. She was one of only six new graduate students in the department and the first female one admitted in nine ...
Recombinant DNA technologies developed in the early 1970s enabled scientists to isolate genes of interest and splice them into existing DNA structures. However, as late as the early 1980s, the ...
After figuring out how to grow recombinant bacteria on an industrial scale and how to harvest the insulin they produce, it was time to bring the recombinant insulin to the market. In 1982 Food and ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...
insights from industryAmy ShengHead of CROSino Biological In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO program at Sino Biological US Inc., about current developments in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback